58,114 Shares in Amicus Therapeutics, Inc. $FOLD Purchased by Caxton Associates LLP

Key Points

• Caxton Associates LLP acquired a new position in Amicus Therapeutics with 58,114 shares valued at approximately $474,000 in the first quarter.
• Amicus Therapeutics shares opened at $8.02, and the stock has a market cap of $2.47 billion, while analysts maintain an average rating of "Moderate Buy" with a consensus target price of $16.00.
• Recent ratings changes show Morgan Stanley upgraded the stock to "overweight," while Wall Street Zen downgraded it from "buy" to "hold," reflecting mixed analyst sentiment.

Caxton Associates LLP bought a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 58,114 shares of the biopharmaceutical company's stock, valued at approximately $474,000.

Other large investors have also added to or reduced their stakes in the company. Virtus Fund Advisers LLC purchased a new stake in Amicus Therapeutics during the 4th quarter valued at about $29,000. PNC Financial Services Group Inc. grew its stake in Amicus Therapeutics by 211.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 3,497 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Amicus Therapeutics during the 4th quarter valued at about $59,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Amicus Therapeutics during the 1st quarter valued at about $53,000. Finally, GAMMA Investing LLC grew its stake in Amicus Therapeutics by 1,610.8% during the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 7,007 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wall Street Zen downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Morgan Stanley upgraded Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday, July 17th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $16.00.

Amicus Therapeutics Price Performance

NASDAQ FOLD traded down $0.26 during trading hours on Monday, reaching $7.73. The company's stock had a trading volume of 3,394,050 shares, compared to its average volume of 3,860,046. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of -64.41 and a beta of 0.55. Amicus Therapeutics, Inc. has a 1-year low of $5.51 and a 1-year high of $12.65. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. The company's 50-day moving average is $6.94 and its two-hundred day moving average is $6.99.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.